The human c-rel gene (REL), encoding an NF-jB transcription factor, is amplified or mutated in several human B-cell lymphomas and can transform chicken lymphoid cells in vitro. We have previously shown that certain deletions of C-terminal transactivation sequences enhance REL's transforming ability in chicken spleen cells. In this report, we have analysed the effect of single amino-acid changes at select serine residues in the Cterminal transactivation domain on REL's transforming ability. Mutation of either of two TNFa-inducible serine residues (Ser460 and Ser471) to nonphosphorylatable residues (alanine, asparagine, phenylalanine) made REL more efficient at transforming chicken spleen cells in vitro.
In contrast, mutation of Ser471 to a phosphorylation mimetic aspartate residue impaired REL's transforming ability, even though it increased REL's inherent transactivation ability as a GAL4-fusion protein. Alanine mutations of several other serine residues within the transactivation domain did not substantially affect REL's transforming ability. Transactivation by GAL4-REL fusion proteins containing either transformation enhancing or nonenhancing mutations at serine residues was generally similar to wild-type GAL4-REL. However, more transforming mutants with mutations at either Ser460 or Ser471 differed from wild-type REL in their ability to transactivate certain jB-site reporter genes. In particular, the SOD2 promoter, encoding manganese superoxide dismutase, was activated less strongly by the more transforming REL mutant REL-S471N in transient assays, but REL-S471N-transformed chicken spleen cells had increased levels of MnSOD protein as compared to wild-type REL-transformed cells. Taken together, our results show that mutations of certain serine residues can enhance REL's transforming ability in vitro and suggest that these mutations increase RELmediated transformation by altering REL's ability to modulate the expression of select target genes. Furthermore, phosphorylation of Ser471 may be involved in RELmediated modulation of transformation-specific target gene expression. Lastly, these results suggest that similar mutations in the REL transactivation domain contribute to the development of certain human B-cell lymphomas.
Introduction
The human proto-oncogene c-rel (herein REL) encodes a transcription factor that is a member of the NF-kB family of proteins, which are involved in the regulation of numerous cellular processes, including proliferation, survival, and apoptosis (Gilmore et al., 2004 ). REL's most notable normal role is in regulating B-and Tlymphocyte functions, such as B-cell proliferation, development, and survival. Thus, it is not surprising that alterations of REL are often associated with human lymphoid malignancies. Amplification of the REL locus is a recurring genetic abnormality in several human Bcell lymphomas, including diffuse large B-cell lymphomas, follicular lymphomas, Hodgkin's disease, primary mediastinal lymphomas, and extranodal lymphomas (Gilmore et al., 2004) . In addition, the REL locus has undergone genetic alterations in one diffuse large B-cell lymphoma cell line (Lu et al., 1991; and in one primary Hodgkin's lymphoma (Barth et al., 2003) , in both cases generating a gene that encodes a C terminally-truncated REL protein.
Alterations in c-rel have also been associated with B-cell oncogenesis in animal model systems. Retroviral integrations in mouse and chicken B-cell lymphomas have been found near the c-rel locus (Kabrun et al., 1989; Hansen et al., 2000) . The viral homolog of REL, v-Rel, is an oncoprotein encoded by the avian Rev-T retrovirus that causes fatal lymphomas in chickens and in transgenic mice (Gilmore, 1999) . Moreover, overexpression of v-Rel or REL can transform primary chicken spleen cells in vitro and these cells can form lethal tumors in chickens (Gilmore, 1999; Gilmore et al., 2001; Starczynowski et al., 2003; Fan et al., 2004) .
Like other NF-kB family proteins, REL contains an N-terminal Rel homology domain (RHD), which mediates DNA binding, dimerization, nuclear localization, and binding to its inhibitor, IkB (Hayden and Ghosh, 2004) . REL can form homodimers and heterodimers with other NF-kB family members, including RelA (p65), p50/p105, and p52/p100. Although the RHD is highly conserved among all NF-kB proteins, the Cterminal halves of these proteins share very little sequence similarity. The C-terminal half of REL (aa 302-587) contains a transactivation domain, which is comprised of at least two subdomains: subdomain I (aa 422-497) and subdomain II (aa 518-587) (Martin et al., 2001; Starczynowski et al., 2003) . Subdomain I is partially required for inducible transactivation by cellular stimuli, such as TNFa and phorbol esters (Martin and Fresno, 2000; Martin et al., 2001) . Conserved serine residues within subdomain I are phosphorylated upon stimulation by PMA/ionophore or TNFa, and mutations at any of several serine residues render REL unresponsive to inducible transactivation (Martin and Fresno, 2000) . In contrast, subdomain II is primarily responsible for basal transactivation by REL (Martin et al., 2001; Starczynowski et al., 2003) .
We have previously shown that deletion of the entire C-terminal transactivation domain abolishes the ability of REL to transform chicken spleen cells in vitro and that the REL transactivation domain can be functionally replaced in transformation assays by a portion of the herpes simplex virus VP16 transactivation domain (Starczynowski et al., 2003) . In contrast, deletion of either transactivation subdomain I or subdomain II alone, which reduces the basal transactivating ability of REL, enhances its transforming ability. Moreover, REL mutants with deletions of C-terminal sequences can also be selected at low frequency in vitro (Starczynowski et al., 2003) . These results indicate that the REL Cterminal transactivation domain serves an essential role in transformation, but that the strength of transactivation can determine the transforming potency of REL.
In this report, we have analysed effect of mutations at individual serine residues within the C-terminal transactivation domain of REL on the transforming ability of REL. Our results show that point mutations at certain serine residues within the C-terminal transactivation domain enhance REL's transforming ability, and suggest that such mutations exist in human B-cell lymphomas.
Results
Residues 424-490 in the transactivation domain of REL reduce its in vitro transforming ability in primary chicken spleen cells
We have previously shown that a REL deletion mutant (RELD424-490) lacking transactivation subdomain I is more transforming than wild-type REL in chicken spleen cells (Starczynowski et al., 2003) . To determine whether the enhanced transforming ability of RELD424-490 is due to it being a shorter protein or due to the lack of specific sequences, we inserted 66 residues from bacterial b-galactosidase (bgal) into the junction between residues 423 and 491 in RELD424-490. The resulting REL mutant, RELD424-490/bgal, contains the same number of amino acids as wild-type REL, but still lacks transactivation subdomain I (Figure 1a) .
Full-length cDNAs for wild-type REL, RELD424-490, and RELD424-490/bgal were subcloned into a spleen necrosis retroviral expression vector and assayed for their ability to transform primary chicken spleen cells using a liquid outgrowth assay . As previously reported, RELD424-490 transformed cells more rapidly (13.3 days) than wild-type REL (17.2 days) (Figure 1b ). RELD424-490/bgal also transformed cells more rapidly (15.5 days) than wildtype REL, however not as rapidly as RELD424-490. As a second measure of transformation, these REL proteins were analysed for their ability to induce colony formation in soft agar (Figure 1b ). Wild-type REL induced colony formation in soft agar only weakly (4 colonies/plate), whereas RELD424-490 was approximately five-to six-fold more potent (22 colonies/plate). Similar to the liquid outgrowth transformation result, RELD424-490/bgal induced colony formation (10 colonies/plate) more effectively than wild-type REL, but less effectively than RELD424-490 (Figure 1b) .
To confirm that these transformed cell cultures were expressing the appropriate-sized proteins, anti-REL Western blotting was performed on extracts from REL-, RELD424-490-, and RELD424-490/bgal-transformed cells using an antiserum against C-terminal residues of REL ( Figure 1c ). As expected, RELD424-490 migrated faster than wild-type REL. Unexpectedly, RELD424-490/bgal also migrated slightly faster than wild-type REL. We have confirmed by DNA sequence analysis of the plasmid and by Western blotting of transiently transfected chicken embryo fibroblasts (CEF) that the altered migration of RELD424-490/bgal is not due to a secondary mutation, such as an internal deletion (not shown). The aberrant migration of RELD424-490/bgal may be due to a structural change imparted by the bgal sequences. Alternatively, REL contains multiple phosphorylation sites in its C-terminal domain (Martin and Fresno, 2000) , and substitution with sequences lacking these phospho-acceptor sites (as in RELD424-490/bgal) may result in a faster migrating protein.
Although REL and RELD424-490 are primarily cytoplasmic proteins in transformed chicken spleen cells, a small percentage of each protein is present in active DNA-binding complexes in the nucleus (Starczynowski et al., 2003) . To determine whether RELD424-490/bgal was also present in the nucleus of transformed cells, extracts from RELD424-490/bgal-transformed spleen cells were analysed in an electrophoretic mobility shift assay (EMSA) using a kB-site probe (Figure 1d ). Nuclear extracts from cells transformed by REL, RELD424-490, and RELD424-490/bgal all contained easily detectable kB site-binding activity. The DNA-binding complexes were almost completely supershifted by anti-REL antiserum, indicating that the REL proteins are the predominant kB site-binding complexes in these cells. RELD424-490 and RELD424-490/bgal nuclear extracts had less kB sitebinding activity than cells transformed by wild-type REL, similar to our previous findings for RELD424-490 (Starczynowski et al., 2003) .
Wild-type REL is a cytoplasmic protein in CEF, whereas RELD424-490 is largely a nuclear protein in these cells (Starczynowski et al., 2003) . To investigate the effect of protein length on the subcellular localization of . The transforming activities of these proteins are shown for liquid outgrowth assays (from two independent experiments performed in triplicate) and soft agar colony formation assays (from two independent assays performed in duplicate). Liquid outgrowth transformation is presented as the average number of days (7standard error) it took for cultures to become transformed. For soft agar colony formation, 4 days after electroporation, cells were placed in soft agar and the numbers of macroscopic colonies per plate were counted 14 days later; values are the average number of colonies (7standard error). (c) Anti-REL Western blotting (using an anti-C-terminal REL antiserum) was performed on equal amount of extracts of spleen cells transformed by REL, Nuclear extracts from cells transformed by the indicated proteins were analysed in a kB-site EMSA. Where indicated, supershifts were performed with preimmune (PI) or anti-REL (REL) antiserum. WGE, wheat germ extract. The DNA-binding complexes and supershifted complexes (SS) are indicated. (e) Indirect immunofluorescence using anti-REL primary antiserum was performed on CEF expressing the indicated proteins C-terminal activating mutations in REL DT Starczynowski et al REL in fibroblasts, CEF were infected with viruses expressing either wild-type REL, RELD424-490, or RELD424-490/bgal and were then analysed by indirect immunofluorescence (Figure 1e ). Consistent with previous results, REL was found largely in the cytoplasm of CEF. On the other hand, RELD424-490 and RELD424-490/bgal were primarily found in the nucleus of these cells (Figure 1e) . Therefore, the addition of the bgal residues to RELD424-490 does not change its primarily nuclear localization in CEF. Taken together, the results in Figure 1 suggest that RELD424-490 is not more transforming simply because REL has been shortened, and that specific residues within aa 424-490 impair REL's transforming ability.
REL C-terminal transactivation domain mutant S471N has an enhanced transforming ability
As deletion or substitution of transactivation subdomain I enhances transformation by REL, we decided to investigate whether mutation of individual residues within transactivation domain I could also enhance REL's transforming ability. A REL mutant (REL-S471N; Figure 2a ) defective in TNFa-induced kB-site transactivation was previously isolated from a mutant Jurkat T-cell clone (Martin and Fresno, 2000) . Unlike wild-type REL, transactivation by REL-S471N cannot be induced above basal levels upon treatment of Jurkat cells with TNFa (Martin and Fresno, 2000) .
As shown in Figure 2b , REL-S471N was able to transform chicken spleen cells significantly faster (Po0.05) than wild-type REL in the liquid outgrowth assay. On average, REL-S471N transformed cells in approximately 17 days, whereas wild-type REL took about 22 days in these specific assays. As expected, RELD424-490 also transformed cells more rapidly than wild-type REL, taking approximately 15 days. As a second and more stringent measure of the transforming activity of REL-S471N, we compared the ability of cells transformed by REL, RELD424-490, and REL-S471N to form colonies in soft agar. For this assay, 1 Â 10 6 cells from liquid cultures transformed by each of these three REL proteins were placed in soft agar and colony formation was scored after 2 weeks. As shown in Figure 2b , cells transformed by wild-type REL formed colonies poorly (B3 colonies/plate), whereas, RELD424-490 (B84 colonies/plate) and REL-S471N (B54 colonies/plate) both formed colonies considerably more efficiently. As evident from the liquid outgrowth assay and from the ability to induce colonies in soft agar, the S471N mutation enhances REL's ability to transform cells in vitro.
Western blotting of extracts from transformed spleen cells confirmed that these cells expressed a REL-S471N protein of the expected size. That is, REL-S471N from transformed spleen cells comigrated on SDS-polyacrylamide gels with REL-S471N synthesized in CEF and with wild-type REL (Figure 2c ). This suggests that the REL-S471N protein did not undergo deletions in the liquid outgrowth transformation assay, and that REL-S471N is inherently more transforming than REL.
Furthermore, nuclear extracts from cells transformed by REL-S471N and REL contain similar levels of kB site-binding activity (Figure 2d ), suggesting that the Liquid outgrowth transformation (from six independent experiments performed with multiple samples) is presented as the average number of days (7standard error) it took for cultures to become transformed. To calculate Relative Transformation, individual samples were normalized to the average number of days it took for cultures to become transformed by wild-type REL (100) in a given experiment; these values were then averaged across all experiments and Relative Transformation is presented as the reciprocal of these results (in order to make the more rapidly transforming REL mutants have a value greater than wild-type REL). For soft agar colony formation, 1 Â 10 6 cells transformed by REL, RELD424-490, and REL-S471N were placed in soft agar and scored for colony formation after 2 weeks (average number of colonies per plate from two independent assays performed in duplicate, 7standard error). (c) Whole-cell extracts from REL or REL-S471N transfected CEF (C) and transformed spleen cells (S) were analysed by anti-REL Western blotting. (d) Nuclear extracts from spleen cells transformed by the indicated proteins or wheat germ extract (WGE) were analysed in a kB-site EMSA. (e) Increasing amounts of in vitro-translated IkBa (0, 0.5, and 1 ml) were added to 5 mg of nuclear extracts from REL-and REL-S471N-transformed spleen cells in an EMSA. The relative amount of REL-DNA complexes remaining after inhibition by IkBa is indicated below each lane C-terminal activating mutations in REL DT Starczynowski et al enhanced transforming ability of REL-S471N is not due to altered DNA binding. C-terminal sequences in RelA have been shown to be involved in binding to IkBa (Ganchi et al., 1992) and mutations in chicken c-Rel that decrease binding to IkBa can increase its transforming ability (Sachdev and Hannink, 1998) . To determine whether the enhanced transforming ability of REL-S471N might be due to resistance to inhibition by IkBa, we investigated whether IkBa can equally inhibit DNA binding by REL and REL-S471N. Nuclear extracts from cells transformed by either REL or REL-S471N were incubated with increasing amounts of in vitro-synthesized IkBa and were then subjected to an EMSA. As shown in Figure 2e , IkBa inhibited DNA binding by REL and REL-S471N to approximately the same extent. This suggests that the enhanced transforming ability of REL-S471N is not due a reduced ability to be inhibited by IkBa.
REL-S471N differs from wild-type REL in its ability to transactivate different kB site-containing promoters
To determine whether REL-S471N has altered transactivation properties in chicken cells, the C-terminal transactivation domain of REL-S471N (aa 278-587) Figure 3 Mutation of Ser-471 affects REL-mediated transcriptional activation. (a) The general structure of wild-type REL protein is shown at the top (RHD, Rel homology domain; TAD, transactivation domain). GAL4-fusion proteins containing C-terminal domains from the indicated proteins were analysed for their ability to activate expression from a GAL4-site luciferase reporter in CEF. Values are relative to the activity seen with GAL4-REL (100) and in all cases are the averages of at least three independent experiments. (b) Induced activation of the indicated GAL4-REL proteins was performed in DF-1 cells. As in (a), GAL4-fusion proteins containing C-terminal domains from the indicated proteins were cotransfected with a GAL4-site luciferase reporter. At 24 h after transfection, cells were starved for 16 h and then were stimulated with TNFa ( þ ) or left untreated (À) (values were normalized to untreated cells in each case). C-terminal activating mutations in REL DT Starczynowski et al was fused to the GAL4 DNA-binding domain (aa 1-147), and a GAL4-site luciferase reporter gene assay was performed in CEF. GAL4-REL-S471N activated transcription to approximately the same extent as wildtype REL (Figure 3a) . Consistent with previous results (Starczynowski et al., 2003) , GAL4-RELD424-490 had an approximately 10-fold reduced transactivating ability. Next, we analysed REL-S471N's ability to respond to TNFa in chicken cells. Expression vectors for GAL4-REL and GAL4-REL-S471N were transfected into the chicken fibroblast DF-1 cell line, and assayed for reporter gene activity in the absence or presence of TNFa (Figure 3b ). Transactivation by GAL4-REL-S471N was not changed by TNFa treatment. In contrast, GAL4-REL transactivation was increased by approximately two-fold upon treatment with TNFa, consistent with previous results in human cells (Martin et al., 2001) . Therefore, the transactivation domain of REL-S471N shows a level of basal transactivation similar to wild-type REL, but its activity cannot be further induced by TNFa in chicken cells.
We next assessed the effects of mutation S471N on REL's ability to activate transcription from different kB site-containing promoters. For these assays, we used A293 cells, which have low endogenous NF-kB activity . Cells were transfected with expression plasmids for either full-length REL, RELD424-490, or REL-S471N and different reporter gene plasmids. REL's transactivation ability was assessed on three reporter gene cassettes: a 3x-kB reporter containing a minimal c-fos promoter downstream of 3 kB sites derived from the MHC-I promoter (Mitchell and Sugden, 1995) ; a reporter containing 1.2 kb of the chicken ikba gene promoter, including 5 kB sites (Schatzle et al., 1995) ; and a reporter containing 3.3 kb of the human manganese superoside dismutase (SOD2) gene promoter (2 kB sites) and 0.4 kb of the SOD2 intronic enhancer (1 kB site) (Abid et al., 2004) . REL-S471N activated approximately two-fold higher than wild-type REL from the 3x-kB promoter (Figure 3c ). REL and REL-S471N activated the IkBa promoter equally well (Figure 3d ). However, REL-S471N and RELD424-490 activated the SOD2 promoter statistically less efficiently than REL (Figure 3e ). Western blotting on extracts used in determining SOD2 reporter gene activities showed that REL and REL-S471N were expressed at similar levels ( Figure 3f ). Taken together, these results show that the S471N mutation alters REL's ability to activate transcription from certain kB site-containing promoters, even under conditions where inducers such as TNFa are not present.
To determine whether the differences in SOD2 reporter gene transactivation by REL and REL-S471N were also reflected in expression from the endogenous SOD2 gene, we compared SOD protein levels in both transiently transfected A293 cells and in stably transformed chicken spleen cells. In A293 cells, RELtransfected cells showed increased levels of endogenous SOD protein as compared to vector-transfected cells, but REL-S471N-expressing cells did not show increased cellular levels of SOD protein (see Figure 4e , below). In contrast, in stably transformed chicken spleen cell cultures, SOD protein levels were higher in cells transformed by REL-S471N than in cells transformed by wild-type REL (Figure 3g ). Therefore, REL-S471N does appear to affect expression of the endogenous SOD protein differently than wild-type REL in two cell types. A likely explanation for these differences in S471N-induced SOD protein expression in A293 versus chicken spleen cells is presented in the Discussion.
A Ser-to-Ala substitution at residue 471 enhances REL's transforming ability, whereas a Ser-to-Asp phosphorylation-mimetic substitution at residue 471 impairs REL's transforming ability As Ser471 can be a site of TNFa-induced phosphorylation (Martin and Fresno, 2000) and because REL-S471N has enhanced transforming ability, we wanted to determine whether phosphorylation-defective (Ala) or phospho-mimetic (Asp) residues at Ser471 would also affect REL's transforming activity. Therefore, we created REL mutants S471A and S471D, which contain Ala or Asp substituted for Ser at residue 471, and assessed their in vitro transforming abilities. As shown in Figure 4a , REL-S471A has an enhanced transforming ability, which is similar to that of REL-S471N. In contrast, REL-S471D has reduced transforming ability in the liquid outgrowth assay as compared to wild-type REL. The reduced transforming ability of REL-S471D is evident by the prolonged time it took to transform spleen cells (B24 versus B21 days), and by the reduced number of transformed plates that emerged as compared to the total number of plates assayed. (In addition, REL-S471D-transformed cells grew slowly and could not be propagated for extended periods of time in liquid culture (not shown).) Western blotting of extracts from infected spleen cells confirmed that these cells expressed REL-S471A and REL-S471D proteins of the expected sizes (Figure 4b ). That is, the REL-S471A and REL-S471D proteins comigrate with wild-type REL.
To determine whether the reduced transforming ability of REL-S471D is due to an altered basal transactivation ability, we assessed the inherent transactivation potential of REL-S471D in GAL4-site reporter gene assays in two cell types (Figure 4c ). DF-1 and A293 cells were transfected with expression vectors for either GAL4 alone, GAL4-REL, GAL4-REL-S471D, or GAL4-REL-S471N, and a GAL4 sitecontaining reporter gene. In both cell types, GAL4-REL activated much stronger than GAL4 alone. GAL4-REL-S471D activated approximately 50% more strongly than wild-type REL in DF-1 cells and 20% more strongly in A293 cells (Figure 4c ). In contrast, GAL4-REL-S471N and GAL4-REL-S471A (see also Figure 7a ) activated to the same level as, or slightly less than, wild-type REL.
Next, we wanted to determine whether REL-S471D exhibited different reporter gene activity as compared to wild-type REL and the more transforming REL mutant REL-S471N. A293 cells were transfected with the SOD2 reporter plasmid and expression vectors for either REL, REL-S471D, or REL-S471N. As shown in Figure 4d , REL-S471D activates the SOD2 reporter as well as wildtype REL. As expected (from Figure 3e) , REL-S471N activated the SOD2 reporter statistically less well than wild-type REL, even though both proteins were expressed at similar levels ( Figure 4d ).
To determine whether these differences in REL transactivation from the SOD2 luciferase reporter plasmid were also reflected in levels of endogenous SOD protein, we performed Western blotting on A293 cells that had been transfected with the REL and REL-S471D expression plasmids. Consistent with the SOD2 reporter gene assays (Figure 4d ), REL-and REL-S471D-expressing A293 cells showed increased levels of SOD protein as compared to vector and REL-S471N transiently transfected cells (Figure 4e ). Taken together, these results show that the presence of an acidic residue in place of Ser471 reduces REL's transforming ability in vitro, and suggest that phosphorylation of Ser471 is not favorable for REL-induced cellular transformation.
Certain other Ser-to-Ala mutants within the REL transactivation domain show enhanced transforming ability in chicken spleen cells
Owing to the enhanced transforming ability of REL-S471N and -S471A, we decided to test additional serine mutants within the REL transactivation domain for REL transactivation subdomain I (aa 422-497) contains several serine residues that are conserved among several species, including human, chimpanzee, rat, and mouse ( Figure 5 ). Three of these serine residues (Ser454, Ser460, and Ser471) have been shown to be necessary for inducible transactivation by REL in response to stimulation by PI3K, PKCz, and/or TNFa, but mutation of these residues has no effect on basal transactivation (Martin et al., 2001) . Therefore, the transforming abilities of several REL Ser-to-Ala mutants (REL-S443,444,447A, REL-S454A, REL-S460A, REL-S471A, REL-S491,494A, and REL-S533,536A) were compared to wild-type REL (Figure 6a ). Mutant REL-S533-536A has mutated serine residues that lie outside subdomain I. We also tested a REL mutant, REL-S460F, which contains a bulky amino acid (phenylalanine) in place of Ser460. As shown in Figure 6a , REL-S460F, REL-S460A, and REL-S471A transformed chicken spleen cells significantly faster (Po0.05) than wild-type REL in the liquid outgrowth assay. On average, wild-type REL took approximately 21 days to transform spleen cells, whereas REL mutants REL-S460F, REL-S460A, and REL-S471A each took approximately 16-17 days to transform these cells. REL-S454A was also significantly faster than wild-type REL, but perhaps slightly less effective than REL-S460A and REL-S471A. REL-S491,494A was only slightly, and not significantly (P>0.09), faster than wild-type REL at transforming cultures (Figure 6a ). In contrast, REL-S443,444,447A and REL-S533,536A transformed cells similarly to wild-type REL. As previously shown (Starczynowski et al., 2003) , RELD424-490 transformed cells significantly more rapidly (B15 days) than wild-type REL. Western blotting on extracts from transformed spleen cells confirmed that all cells synthesized REL proteins of the expected sizes ( Figure 6b) .
As a second measure of transformation, we examined the ability of REL serine mutants to induce colony formation in soft agar. As shown in Figure 6c , cells transformed by REL-S460F, REL-S460A, and REL-S471A formed colonies in soft agar more efficiently than cells transformed by wild-type REL. In contrast, cells transformed by REL-S443,444,447A, REL-S454A, REL-S491,494A, and REL-S533,536A were less efficient than cells transformed by Ser460 and Ser471 mutants at forming colonies in agar and were more similar to cells transformed by wild-type REL. As expected, REL only weakly formed colonies (B19 colonies/plate) and RELD424-490 efficiently induced colony formation (B127 colonies/plate). These results show that mutation of particular serine residues (i.e. Ser460 and Ser471) can enhance REL-mediated transformation in vitro, but disruption of other serine residues within subdomain I does not confer upon REL an increased transforming ability.
The enhanced transforming ability of REL Ser460 mutants correlates with differential reporter gene transactivating ability
To determine whether the enhanced transformation by some REL serine mutants was due to an altered basal transactivation ability, we assessed the inherent transactivation ability of the panel of REL serine mutants in GAL4-site reporter gene assays in CEF (Figure 7a ). GAL4-fusion proteins containing wild-type REL sequences or sequences from the REL point mutants activated transcription to approximately the same extent. This result is consistent with similar experiments performed in Jurkat cells (Martin et al., 2001 ) and with (Figure 3a) . Our results show that these single serine mutations in the C-terminal domain of REL do not affect basal transcriptional activation in the context of a GAL4-fusion protein and suggest that a reduced level of basal transactivation by REL is not absolutely necessary for enhanced transformation in vitro.
As REL-S471N shows a kB-site transactivation profile distinct from wild-type REL, we wanted to determine whether other more transforming REL mutants exhibit different reporter gene activities. A293 cells were transfected with expression vectors for either REL or the REL C-terminal Ser mutants and with either a 3x-kB-site reporter or a kB-site reporter containing sequences from the human SOD2 promoter. Wild-type REL activated the 3x-kB reporter approximately sixfold more strongly than the empty vector control; all REL point mutants activated statistically similar to REL (Figure 7b ). In SOD2 promoter-containing reporter assays, more transforming REL mutants (REL-S460F, REL-460A, and REL-S471A) activated statistically less than wild-type REL, whereas REL mutants (REL-S443,444,447A and REL-S533,536A) that transformed cells similarly to REL also activated the SOD2 reporter to approximately the same level as REL (Figure 7c ). All transfected REL proteins were overexpressed to approximately the same extent (Figure 7d ). Of note, REL-S454A activated the SOD2 reporter less efficiently than REL. REL-S454A induced colonies in soft agar similar to wild-type REL, but was more transforming than REL in the liquid outgrowth assay (Figure 6a, c) . Thus, REL mutants (REL-S460F, REL-S460A, REL-S454A) with increased transforming abilities in liquid outgrowth assays also uniformly exhibit reduced reporter gene transactivation from the SOD2 reporter as compared to wild-type REL or REL mutants that are not more transforming.
Discussion
In this report, we show that mutation of certain serine residues (Ser460 and Ser471) within REL transactivation subdomain I enhances REL's transforming ability in vitro. Although mutation of these serine residues does not alter inherent basal transactivation by REL, they do reduce REL-directed transactivation in response to certain inducers and alter REL's ability to transactivate the human SOD2 kB site-dependent promoter (Table 1) . These results suggest that single amino-acid changes that alter REL's transactivating ability can also enhance REL's transforming activity.
Alterations in transactivation enhance REL-mediated transformation
A recurring theme in Rel-mediated transformation is that alterations in Rel's transactivation activity can lead to enhanced transforming ability. The highly oncogenic v-Rel protein has a deletion that removes part of the C-terminal transactivation domain of c-Rel, and many C-terminal deletion mutants of chicken c-Rel are more transforming than wild-type c-Rel in vitro (Gilmore, 1999) . Moreover, c-Rel proteins that have deletions of C-terminal transactivation sequences often arise in chicken lymphoid cells infected with retroviral expression vectors for wild-type chicken c-Rel (Hrdlickova´et al., 1994; Gilmore et al., 1995) . Similarly, some human Figure 2b . Data represent the average number of colonies per plate from four independent assays. Numbers are relative to RELD424-490 (100), which on average formed 127 colonies/plate. Error bars designate standard error C-terminal activating mutations in REL DT Starczynowski et al REL deletion mutants (RELD424-490 and RELD58) with approximately 10-fold reduced transactivation, as measured in GAL4-fusion assays, transform chicken spleen cells more efficiently than wild-type REL (Starczynowski et al., 2003) . When the REL transactivation domain is replaced by the entire VP16 transactivation domain, which activates 10-fold more strongly than the wild-type REL transactivation domain, the REL-VP16 chimeric protein does not transform chicken spleen cells. However, when the REL C-terminal transactivation domain is replaced by a portion of the VP16 transactivation domain (VP16DN) that activates at a level approximately five-fold lower than REL, this REL-VP16 chimeric can now transform these cells (Starczynowski et al., 2003) . The importance of transactivation sequences in transformation has also been demonstrated by analyzing RelA/v-Rel hybrid proteins. Wild-type RelA cannot transform chicken spleen cells; however, when the RelA transactivation domain is replaced by the less active transactivation domain of v-Rel, the RelA/v-Rel fusion protein can now transform these cells (Fan et al., 2004) . Finally, there are at least two cases of human B-cell lymphomas wherein alterations of the REL locus result in C terminally-truncated REL proteins that are missing transactivation domain sequences (Lu et al., 1991; Barth et al., 2003) . However, there have been no previous reports of point mutations in the REL transactivation domain that can enhance its transforming ability in vitro, nor have REL point mutations been found in human lymphomas.
How might serine mutations in the C-terminal transactivation domain enhance REL's transforming ability?
In this paper, we show that certain mutations of serine residues Ser460 or Ser471 in the C-terminal transactivation domain enhance REL's transforming ability. We believe there are at least three hypotheses for how mutation of these serine residues in the REL transactivation domain contributes to enhanced transformation: (1) they generally reduce the basal level of transactivation by REL; (2) they may increase or decrease REL-mediated transactivation of key target gene promoters; or (3) they reduce inducible transactivation by REL. There are no dramatic changes in basal transactivation by these REL point mutants as GAL4-fusion proteins in chicken or human cells (Figures 3a  and 6a) , suggesting that the first hypothesis is not correct. However, REL proteins with alanine, asparagine, or phenylalanine substitutions at Ser454, Ser460, and Ser471, which transformed more effectively than wild-type REL in liquid transformation assays, activated transcription less than wild-type REL from a kBsite reporter plasmid containing part of the human SOD2 promoter (Table 1) . This result is consistent with the second hypothesis. Of note, certain oncogenically activating mutations at serine residues in c-Myc also do not change c-Myc's inherent transactivating potential as GAL4-fusion proteins but do affect transactivation from a c-Myc-reponsive reporter (Smith-Sorensen et al., 1996) .
In one scenario, wild-type REL may activate a subset of target genes whose expression is not entirely compatible with the transformed state, and certain oncogenic REL mutants may activate these target genes less effectively, while still efficiently activating transformation-inducing target genes. This model is consistent with the finding that REL-S471N activates better than REL from the artificial 3x-kB promoter, equally well from the IkBa promoter, but less well from the SOD2 promoter (Figure 3 ). Similar to our results, a recent study showed that a truncated REL protein missing 112 C-terminal aa transactivated the IL-2 promoter more strongly than wild-type REL, but transactivated the IkBa promoter weaker than wild-type REL (Iwai et al., 2005) . Moreover, v-Rel exhibits differential activation of certain target genes as compared to chicken c-Rel, and this difference is likely to contribute to v-Rel's ability to transform cells more efficiently than c-Rel (Schatzle et al., 1995; Kralova et al., 1998 Kralova et al., , 2002 Hrdlickova´et al., 2001 ). In particular, Kralova et al. (2002) found that chicken c-Rel activates the IAP1 promoter more efficiently than v-Rel in transient transfection assays; however, v-Rel induces IAP1 mRNA and protein more efficiently than c-Rel in stably transformed long-term chicken cell cultures. This is similar to our results wherein we have found that wild-type REL induces SOD2 promoter expression in transient assays more efficiently than the more transforming REL-S471N mutant, but the SOD2 protein levels are higher in chicken cells stably transformed by REL-S471N than in cells transformed by REL. Thus, the ability of certain REL mutants to induce sustained low-level expression of some genes, such as IAP1 and SOD2, may ultimately result in higher long-term expression and be more oncogenic. Interestingly, SOD2 mRNA expression is elevated in human mediastinal lymphomas with increased levels of nuclear REL (Feuerhake et al., 2005) .
Transactivation domain mutants could differentially affect REL activity at different promoters either by affecting transactivation directly or by affecting DNA binding. For example, Leung et al. (2004) have shown that single mutations in a kB site can alter which coactivators interact with NF-kB proteins bound to these sites. This indicates that not only is the kB-site sequence important for determining NF-kB dimer binding specificity, but the kB site sequence also determines which coactivators will bind to NF-kB dimers. Similarly, transactivation domain mutants that affect REL coactivator interactions may influence their kB site binding ability and, thus, their ability to transactivate different promoters.
REL C-terminal transactivation subdomain I contains at least seven serine residues that are necessary for inducible transactivation (Martin et al., 2001) , and most of these residues are conserved among several mammalian c-Rel proteins ( Figure 5 ). Mutation of serines 454, 460 or 471 to alanine impairs TNFa-induced Transactivation by GAL4-REL fusion proteins in chicken fibroblasts. +, transactivation similiar to REL; ++ transactivation signifcantly (Po0.05) higher than REL. (Martin et al., 2001) , and mutation of Ser471 to asparagine decreases phosphorylation within the REL C-terminal domain (Martin and Fresno, 2000) . These TNFa-responsive serine residues in REL are likely to be sites of phosphorylation catalysed by a kinase(s) downstream of the TNFa receptor signaling cascade, which facilitates transcription of TNFa-targeted REL-dependent genes. The identity of such kinases is not known, but several kinases have been shown to directly or indirectly affect REL's transactivation ability. For example, expression of PKCz or stimulation with IP 3 leads to enhanced transactivation levels by REL (Martin et al., 2001) , and extracts from PMA/ionophore or TNFa-stimulated Jurkat cells can phosphorylate recombinant wild-type REL (aa 464-481) but not REL-S471N (Martin and Fresno, 2000) . In addition, PKA-Cb and IKKa have been shown to alter REL's transactivating ability by directly phosphorylating the C-terminal domain (Yu et al., 2004; Lawrence et al., 2005) . Furthermore, CDK2/cyclinE can directly interact with the REL transactivation domain in vitro (Chen and Li, 1998) . Mutation of certain serine residues in the transactivation domain of v-Rel has also been shown to affect its phosphorylation state and its transforming and transactivating abilities (Rayet et al., 2003) ; however, because there is only weak sequence similarity between the transactivation domains of v-Rel and REL, it is not clear if any of the serine residues that were analysed in that prior work correspond to those analysed herein in REL. Curiously, in dog and cow, the residues that correspond to human REL Ser460 and Ser471, which are the serines most susceptible to transformation-enhancing substitution mutations in our assays, are Pro and Asn, respectively ( Figure 5 ).
Nonphosphorylatable REL mutants at Ser460 or Ser471 may transform chicken lymphoid cells more efficiently because they lack a TNFa-responsive serine residue and therefore transactivate certain genes aberrantly, even in the absence of a specific activating agent. Conversely, REL-S471D may have reduced transforming activity because it transactivates certain genes at the level of a constitutively active REL protein. Indeed, GAL4-REL-S471D is a more potent activator than GAL4-REL (Figure 4c ). Relevant to this discussion, our transformation assays are performed in the presence of high levels (20%) of fetal bovine serum (FBS), which may have factors that can activate pathways leading to chronic activation of REL through Ser460 and Ser471. Under these conditions, transactivation by fully activated, overexpressed wild-type REL may be detrimental to transformed cell viability, a response that could be a mechanism to prevent uncontrolled cell proliferation promoted by an oncogenic transcription factor. For instance, high expression of REL in the avian embryo is correlated with elevated apoptosis of several cell types, including bone marrow cells and thymocytes (Abbadie et al., 1993; Huguet et al., 1999) . In addition, overexpression of human or chicken c-Rel inhibits proliferation and increases apoptosis in HeLa cells (Bash et al., 1997; Bernard et al., 2001) . Interestingly, it has been reported that REL initially protects HeLa cells from TNFa-induced cell death, but sustained expression of REL later increases the level of apoptosis (Bernard et al., 2002) . Thus, the paradoxical control of cell survival by REL may represent a delicate balance between signals that promote apoptosis and proliferation.
Although we have shown that the mutation of certain serine residues necessary for TNFa-induced activation of REL enhances spleen cell transformation, we do not know whether TNFa has a role in REL-mediated transformation. The TNFa receptor activates multiple signaling pathways, and a number of downstream proteins may act on REL. In any case, our results predict that mutations of serine residues within the REL C-terminal transactivation domain will be identified in some human B-cell lymphomas.
Materials and methods

Plasmids
DNA manipulations were carried out by standard methods (Sambrook et al., 1989) . Complete details of all subclones and primers used in this study can be obtained at www.nf-kb.org.
Spleen necrosis virus vectors JD-REL and JD-RELD424-490 have been described previously Starczynowski et al., 2003) . pCMV-REL was a kind gift from Inder Verma (Salk Institute). pRc/CMV-REL-S471N was a kind gift from Manuel Fresno (University of Madrid, Spain). pUC18-REL-S443,444,447A, -S454A, -S460A, -S491,494A, and -S533,536A (from M Fresno) were digested with SwaIXhoI and the fragments containing the mutation were used to replace the corresponding fragment in pGEM-RELD424-490 (Starczynowski et al., 2003) . REL-S471A and REL-S471D were created by standard PCR mutagenesis techniques. RELD424-490/bgal was created by subcloning an EcoRVSwaI fragment from a PCR-amplified portion of the lacZ gene of Bluescript KS þ into pGEM-RELD424-490 digested with SwaI. Subsequently, a SwaI fragment from wild-type REL was subcloned into the intermediate pGEM-REL plasmid digested with SwaI. For, JD-RELD424-490/bgal, an XbaI-NdeI fragment from pGEM-RELD424-490/bgal replaced an XbaI-NdeI fragment from JD-RELD424-490. JD214 retroviral vectors for the expression of REL mutants in chicken cells were made by subcloning EcoRV-HindIII fragments into EcoRV-HindIIIdigested JD-RELD424-490. Plasmids for the expression of full-length REL proteins in A293 cells were made by subcloning XbaI-HindIII fragments into XbaI-HindIII-digested pcDNA3.1(À) (Invitrogen, Carlsbad, CA, USA). REL-S460F was isolated as a spontaneous REL mutant in yeast. pGK-bgal has been described previously (Wang and Gilmore, 2001 ). GAL4 expression plasmids pSG424 (aa 1-147 of GAL4) and pSG-REL (REL aa 278-587), reporter plasmid GAL4-site luc, and transfection normalization plasmid pCMV-bgal have been described previously (Epinat et al., 2000; Wang and Gilmore, 2001; Starczynowski et al., 2003) . Plasmids for the expression of GAL4-REL C-terminal point mutant fusions were made by subcloning BamHI-KpnI fragments into BamHI/KpnI-digested pSG424.
Cells and spleen cell transformation assays
CEF, DF-1 chicken fibroblasts, A293 human embryonic kidney cells, and transformed chicken spleen cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10-20% FBS (Biologos, Montgomery, IL, USA), 50 U/ml penicillin, and 50 mg/ml streptomycin.
As described previously, spleen cell transformation was measured either in liquid outgrowth assays or by the formation of colonies in soft agar (Mosialos et al., 1991) . Spleen necrosis virus vectors for the expression of the indicated genes and RevA helper virus DNA were coelectroporated into primary chicken spleen cells taken from 19-day-old chickens (Charles River SPAFAS, Franklin, CT, USA). For liquid outgrowth assays, transformation was measured as the number of days it took for transformed cells to overgrow the culture. For colony formation assays, RELtransformed cells were passaged in liquid culture for approximately 2 weeks after they had been scored as transformed and then 1 Â 10 6 cells were placed into an agar mix containing DMEM, 20% FBS, and 0.3% bacto-agar. Alternatively, 4 days after electroporation, spleen cells were placed into an agar mix. In both cases, colony formation was scored after 14 days. Transformed spleen cell cultures used for Western blotting were generated by continued passaging of cells from liquid outgrowth transformation assays.
Western blotting and indirect immunoflourescence
Whole-cell extracts for chicken spleen cells were obtained by directly resuspending cell pellets in 2 Â SDS sample buffer (125 mM Tris, pH 6.8, 4.6% w/v sodium dodecyl sulfate, 20% w/v glycerol, 10% v/v b-mercaptoethanol, 0.2% w/v bromophenol blue), and heating samples at 951C for 10 min. A293 cell extracts were prepared 2 days after transfection by lysing cells in Reporter Lysis Buffer, and extracts were normalized according to transfection efficiency as measured by the bgalactosidase activity (see Luciferase reporter assays below). Equalized A293 cell lysates were then resuspended in SDS sample buffer and heated at 951C. Proteins were separated on SDS-polyacrylamide gels, transferred onto nitrocellulose membranes (Osmonics, Westborough, MA, USA), probed with primary and secondary antisera, and visualized using the Pierce SuperSignal West Dura Extended Duration Substrate (Pierce, Rockford, IL, USA) as described previously (Starczynowski et al., 2003) . The REL antiserum used for Western blotting was raised against the epitope NEQLSDSF-PYEFFQV (REL C-terminal amino acids), and was a kind gift from Nancy Rice . The rabbit anti-SOD antiserum (Abcam Inc., Cambridge, MA, USA) was used at a dilution of 1 : 2000, and the rabbit antitubulin antiserum (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was used at a dilution of 1 : 500.
For immunofluorescence, CEF were passaged 4 days after transfection onto glass coverslips. Indirect immunofluorescence using anti-REL primary antiserum (1 : 50) and FITCconjugated goat anti-rabbit IgG secondary antibody (1 : 80; Sigma, St Louis, MO, USA) was performed as described previously (Starczynowski et al., 2003) . Cells were visualized on an Olympus confocal microscope.
Electrophoretic mobility shift assay
EMSAs were performed using nuclear extracts prepared essentially as described previously (Schreiber et al., 1989; Starczynowski et al., 2003) with the inclusion of 1 mM DTT, 5 mg/ml leupeptin, 62.5 mg/ml aprotinin, 1 mg/ml pepstatin, and 1 mM PMSF. Protein concentrations were determined using the Bio-Rad (Hercules, CA, USA) protein assay reagent. DNA-binding reactions were performed in a final volume of 50 ml containing 10 mM Tris, pH 7.4, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 4% w/v glycerol, 2 mg poly dI/dC, 10 000 cpm of 32 P end-labeled kB site (underlined) probe (5 0 TCGAGAGGTCGGGAAATTCCCCCCCG3 0 ), and 5 mg of nuclear extract. Samples were incubated at room temperature for 30 min. Complexes were resolved on 5% polyacrylamide Tris-glycine-EDTA gels, which were electrophoresed at 60 mA for approximately 1.5 h. Gels were dried and autoradiography was performed. For supershift assays, 1 ml of antiserum was added after protein/DNA complex formation and the reactions were incubated on ice for 1 h. The anti-REL antibody is specific for an epitope near the C terminus of the RHD (a kind gift from Nancy Rice; .
For DNA-binding inhibition studies, IkBa was synthesized in vitro (Promega, Madison, WI, USA) and various concentrations of in vitro-translated IkBa were incubated with nuclear extracts for 1 h on ice prior to DNA-protein complex formation.
Luciferase reporter assays
CEF, DF-1 or A293 cells in 60 mm plates were transfected with 0.3 mg. of reporter plasmid GAL4-site luc, 0.5 mg of normalization plasmid pCMV-bgal, and 2 mg of pSG424-based GAL4 expression plasmids using the DMSO/polybrene method as described previously (Starczynowski et al., 2003) . As previously described , A293 cells in 35 mm plates were transfected with 0.5 mg of luciferase reporter plasmid, 0.5 mg of pGK-bgal, and 1 mg of the given pcDNA expression plasmid using the Superfect Reagent according to the manufacturer's recommendations (Qiagen, Valencia, CA, USA).
Luciferase activity was measured using the Luciferase Assay System according to the manufacturer's instructions (Promega, Madison, WI, USA). Luciferase values were normalized to b-galactosidase values in all assays, as described previously . The 3x-kB-Luciferase-pGL2 reporter plasmid has a minimal c-fos promoter element and three copies of the major histocompatibility complex (MHC) class I kB element TGGGGATTCCCCA (Mitchell and Sugden, 1995) . The IkB-Luciferase-pGL2 reporter plasmid contains a 1.3 kb HindIII-EcoRI fragment of the chicken IkBa genomic clone, containing the transcriptional start site and 900 bp of upstream sequence (Schatzle et al., 1995) . The SOD-Luciferase-pGL3 reporter plasmid contains 3.3 kb of the human SOD2 gene promoter and 0.4 kb of the SOD2 intronic enhancer (Abid et al., 2004) .
For TNFa induction, DF-1 cells transfected with pSGS424-based GAL4 expression plasmids were incubated in DMEM/ 10% FBS. After 24 h, cells were starved in DMEM/1% FBS for 16 h, followed by treatment with 20 ng/ml TNFa (R&D Systems, Minneapolis, MN, USA) for 5 h.
Statistical analysis
Results are expressed as mean values7standard error. A P-value o0.05 was deemed significant. Statistical significance of the data was analysed by the Student's t-test using Prism 2.0. 
